Guardant Health - Stock Price History | GH

Historical daily share price chart and data for Guardant Health since 2021 adjusted for splits. The latest closing stock price for Guardant Health as of September 27, 2021 is 125.72.
  • The all-time high Guardant Health stock closing price was 179.10 on February 12, 2021.
  • The Guardant Health 52-week high stock price is 181.07, which is 44% above the current share price.
  • The Guardant Health 52-week low stock price is 96.66, which is 23.1% below the current share price.
  • The average Guardant Health stock price for the last 52 weeks is 129.62.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Guardant Health Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 91.1161 79.4100 135.9300 59.0400 128.8800 64.93%
2019 73.1887 36.5000 110.3000 34.3000 78.1400 107.87%
2018 36.8405 32.2000 46.1000 29.2000 37.5900 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $12.735B $0.287B
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29